The growing number of detected tyrosine kinase fusions in predominantly EGFRwt/KRASwt adenocarcinomas (including ALK, RET, and ROS1) are also becoming increasingly important in the therapeutic setting, as these alterations are/may become targets for specialized molecular agents. The gene discussed is ALK; the disease is adenocarcinoma.